Hemay181 is a potentially first-in-class Sugar-based Drug Conjugate (SDC) targeting topoisomerase I, activated by the tumor microenvironment, with broad antitumor growth inhibition. Hemay181 also possesses tumor-targeting properties and high drug efficiency.
1Trial Title:A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor efficacy of Hemay181 in patients with advanced solid tumors.
Target Population： Patients with advanced solid tumors
Clinical Project Description： A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor efficacy of Hemay181 in patients with advanced solid tumors.
